FDA Issues Warning Letter to Beta Bionics Over Quality System Issues

Beta Bionics, the maker of the iLet Bionic Pancreas automated insulin delivery system, has received a warning letter from the US Food and Drug Administration (FDA) following a facility inspection conducted last year. The company disclosed in a securities filing that the letter, received on 29 January, cites non-conformities related to its quality management system, medical device reporting, and corrections and removals. The warning letter has not yet been posted publicly by the FDA.

The action follows a Form 483 issued after an FDA inspection of Beta Bionics’ Irvine, California site in June. Beta Bionics said it has already taken steps to address the issues and is preparing a formal written response to the agency.

The company does not expect the warning letter to impact its ability to manufacture, market, or distribute products, nor does it anticipate delays to the planned Mint insulin patch pump, targeted for launch by the end of 2027. Analysts described the letter as unwelcome but not disruptive, citing management’s confidence.

09-02-2026